Andrew Hollman Meyer Sells 3,333 Shares of Janux Therapeutics (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 3,333 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $32.98, for a total value of $109,922.34. Following the completion of the transaction, the insider directly owned 84,974 shares of the company’s stock, valued at approximately $2,802,442.52. This trade represents a 3.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Andrew Hollman Meyer also recently made the following trade(s):

• On Friday, November 14th, Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $99,990.00.
• On Tuesday, October 28th, Andrew Hollman Meyer sold 16,665 shares of Janux Therapeutics stock. The stock was sold at an average price of $30.06, for a total transaction of $500,949.90.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock opened at $16.40 on Friday. The firm has a market cap of $986.46 million, a P/E ratio of -9.76 and a beta of 2.82. The firm’s 50-day simple moving average is $26.93 and its 200-day simple moving average is $25.25. Janux Therapeutics, Inc. has a twelve month low of $15.51 and a twelve month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million for the quarter, compared to the consensus estimate of $3.07 million. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Janux Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in JANX. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Janux Therapeutics by 26.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,125 shares of the company’s stock valued at $192,000 after purchasing an additional 1,488 shares during the period. US Bancorp DE raised its stake in shares of Janux Therapeutics by 2,402.9% during the first quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after buying an additional 1,658 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Janux Therapeutics by 6.7% in the first quarter. Vanguard Group Inc. now owns 2,278,660 shares of the company’s stock valued at $61,524,000 after buying an additional 142,328 shares during the period. Deutsche Bank AG boosted its stake in Janux Therapeutics by 7.2% in the first quarter. Deutsche Bank AG now owns 99,691 shares of the company’s stock valued at $2,692,000 after acquiring an additional 6,662 shares during the last quarter. Finally, Nuveen LLC bought a new position in Janux Therapeutics in the first quarter valued at approximately $3,339,000. 75.39% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

JANX has been the topic of a number of analyst reports. Wedbush reiterated an “outperform” rating and issued a $45.00 price target (down from $76.00) on shares of Janux Therapeutics in a research report on Tuesday. Truist Financial assumed coverage on shares of Janux Therapeutics in a research note on Wednesday, September 10th. They issued a “buy” rating and a $100.00 target price on the stock. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Barclays boosted their price target on shares of Janux Therapeutics from $47.00 to $48.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Wolfe Research started coverage on shares of Janux Therapeutics in a report on Tuesday, November 18th. They set a “peer perform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.67.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.